The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
In this role, Jeffrey DeAlmeida takes responsibility for BASF’s global pharmaceutical solutions portfolio and the Nutrition & Health business in North and South America
These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Tamper evident caps with incorporated RFID technology offer a significant reduction in RFID implementation costs
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
100% efficacy against severe Covid-19 disease and hospitalizations
Methodology developed by QIMR Berghofer researchers utilizing the Agilent Cary 630 FTIR
Modi holds a bachelor's degree in Chemical Engineering from University of Cincinnati and a master’s degree in Marketing, Management Strategy and Finance from Northwestern’s Kellogg School of Management
Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline
Subscribe To Our Newsletter & Stay Updated
